Compare DexCom, Inc. (DXCM) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Valero Energy Corporation — how do they compare? DexCom, Inc. trades at $84.91 (market cap $31.86B), while Valero Energy Corporation trades at $442.95 (market cap $127.78B). The key difference: Valero Energy Corporation is far larger — about 4× DexCom, Inc.'s market cap, and Valero Energy Corporation pays a 1.08% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Valero Energy Corporation for 56 Days on average.
| DXCM | VLO | |
|---|---|---|
Market Cap | $31.86B | $127.78B |
Volume | 3,607,070 | 2,570,225 |
Sector | Health | Energy |
52-Week High | $92.34 | $443.80 |
52-Week Low | $54.84 | $156.39 |
Typical Hold Time | 62 Days | 56 Days |
Enterprise Value | $31.32B | $131.26B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
Valero Energy (VLO) trades at $424.10, up 1.16% today, near its 52-week high. The stock exhibits bullish technical signals with strong moving average alignment and has beaten earnings estimates for three consecutive quarters. Revenue declined to $122.69 billion in 2025, but net income margin improved to 5.17%. Analyst consensus is bullish with a $408.10 price target, and recent news highlights institutional buying and refining margin strength.
Outlook remains positive driven by earnings beats and supportive refining margins, but risks include potential diesel export policy changes and volatile energy markets. The stock's high RSI suggests near-term overbought conditions, yet fundamental improvements and strong cash flow projections for 2026 provide a solid foundation for continued investor interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
